207 related articles for article (PubMed ID: 19856075)
1. Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Suzuki S; Ishikawa K
J Infect Chemother; 2009 Oct; 15(5):335-9. PubMed ID: 19856075
[TBL] [Abstract][Full Text] [Related]
2. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
[TBL] [Abstract][Full Text] [Related]
3. Outpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer.
Maeda M; Yamashita T; Matsunobu T; Araki K; Tomifuji M; Shiotani A
Anticancer Res; 2013 Aug; 33(8):3285-9. PubMed ID: 23898093
[TBL] [Abstract][Full Text] [Related]
4. Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
Yamashita T; Shinden S; Watabe T; Shiotani A
Anticancer Res; 2009 Feb; 29(2):577-81. PubMed ID: 19331206
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
[TBL] [Abstract][Full Text] [Related]
6. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1151-8. PubMed ID: 9679577
[TBL] [Abstract][Full Text] [Related]
7. [Late phase II study of S-1 in patients with advanced head and neck cancer].
Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B;
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1381-90. PubMed ID: 11681245
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Suzuki S; Honda K; Sato T; Yamazaki K; Ishikawa K
J Chemother; 2015 Oct; 27(5):297-300. PubMed ID: 25971448
[TBL] [Abstract][Full Text] [Related]
9. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
Tsukuda M; Kida A; Fujii M; Kono N; Yoshihara T; Hasegawa Y; Sugita M;
Br J Cancer; 2005 Oct; 93(8):884-9. PubMed ID: 16189518
[TBL] [Abstract][Full Text] [Related]
10. Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer.
Furusaka T; Tanaka A; Matsuda H; Ikeda M
Acta Otolaryngol; 2011 Oct; 131(10):1099-103. PubMed ID: 21651316
[TBL] [Abstract][Full Text] [Related]
11. [Indication of alternate-day treatment with S-1 in patients with oral cancer].
Negishi A; Ogawa M; Kosugi K; Takayama Y; Gomi A; Miyazaki H; Yokoo S
Gan To Kagaku Ryoho; 2015 May; 42(5):569-73. PubMed ID: 25981649
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
Tanigawa T; Matoda M; Yamamoto A; Nomura H; Okamoto S; Sakamoto K; Kondo E; Omatsu K; Kato K; Takeshima N
Arch Gynecol Obstet; 2016 Mar; 293(3):633-8. PubMed ID: 26305033
[TBL] [Abstract][Full Text] [Related]
13. [Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment].
Katsuno M; Watanabe N; Sugio Y; Tachibana S; Tani Y; Sato N; Zusho H
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2109-13. PubMed ID: 21084809
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Peng PJ; Cheng H; Ou XQ; Zeng LJ; Wu X; Liu YM; Lin Z; Tang YN; Wang SY; Zhang HY; Chen ZB
Drug Des Devel Ther; 2014; 8():1083-7. PubMed ID: 25152614
[TBL] [Abstract][Full Text] [Related]
16. [Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
Nishino H; Shinozaki T; Ishikawa K; Tanaka H; Ichimura K
Gan To Kagaku Ryoho; 2002 Nov; 29(11):2019-23. PubMed ID: 12465408
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():144-9. PubMed ID: 16897991
[TBL] [Abstract][Full Text] [Related]
18. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
19. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
20. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
